Pharma stocks
Drug Behaviour in India: Sun Pharmaceutical Industry, Lupin and other Indian drug behaviour negotiated at deep discounts after President Donald Trump announced 100% higher prices in businesses and announced patented drug imports from October 1, 2025 if they have not built a production company in the US since October 1, 2025. In its social services position, Trump explained that if construction has already begun at a production plant in the US, the price does not apply to drugs. Starting October 1, 2025, you will enter a 100% fee for branded or patented medicines unless your company builds a drug production plant in the United States. “Building” is defined as “breaking land” and/or “under construction.” So, if construction begins, there will be no prices for these medicines,” Trump wrote. Advice on promoting exports of medicines from India shows that the US represents around 35% of Indian drug exports at around 35% of $10 billion, so analysts warn that this step can put pressure on Indian drug exporters.
Prices are primarily aimed at proprietary drugs, but there is ambiguity examining whether complex generics and special drugs could also have an impact, which could cause problems for businesses that are primarily based on exports to the US. But companies already building construction companies in the US will be open to the public, offering the possibility of easing the pricing exhibition,” said Maitri Sheet of Pharma & Healthcare Analyst in his institutional option measures. Currently, generics are drugs, and separate investigations under Section 232 of the US Trade Division, so drugs, organic drugs and special drugs remain excluded from the new prices.
India remains the largest general supplier in the US, exporting $3.7 billion worth of dollars in the first half of 2025. “The direct short-term impact on Indian pharmacies is limited as prices are aimed at brands/patent drugs dominated by global innovators. There is uncertainty and is linked to the purpose of these complex/professional generics of growing attention among Indian players. The US remains the largest market for farms in India. As a result, it highlighted to parliamentary analysts that expanding tariff compensation could significantly change the growth/export trajectory.
